SG Americas Securities
CRL icon

SG Americas Securities’s Charles River Laboratories CRL Stock Holding History

SG Americas Securities’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-49,000
Closed -$131K – 2975
2015
Q4 		$131K Buy
+49,000
New +$3.53M ﹤0.01% 2289

Other funds holding CRL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

SG Americas Securities's CRL Position: Q2 2026 in Review

SG Americas Securities reduced its Charles River Laboratories (CRL) stake by 91% in Q2 2026, selling an estimated $30M and leaving 17,453 shares worth $3.96M. The position accounts for ﹤0.01% of the portfolio, ranked #1193.

SG Americas Securities first reported a position in CRL in Q2 2013 and has held it in 50 quarters since. The position peaked at $40.2M in Q1 2025. 570 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • SG Americas Securities held 17,453 shares of Charles River Laboratories worth $3.96M as of Q2 2026.
  • SG Americas Securities sold 168,720 Charles River Laboratories shares in Q2 2026, an estimated $30M.
  • Charles River Laboratories made up ﹤0.01% of SG Americas Securities's portfolio in Q2 2026, its #1193 holding.
  • SG Americas Securities first reported a position in Charles River Laboratories in Q2 2013 and has held it in 50 quarters since.
  • SG Americas Securities's Charles River Laboratories position peaked at $40.2M in Q1 2025.
  • 570 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on SG Americas Securities's 13F filing for Q2 2026, filed 7 Aug 2026.